New drug duo targets tough stomach cancer before surgery
NCT ID NCT07581574
First seen Jun 14, 2026 · Last updated Jun 16, 2026 · Updated 1 time
Summary
This early-phase trial tests a combination of two drugs (Trastuzumab rezetecan and retlirafusp alfa) in 12 people with a specific type of stomach cancer that is HER2-positive and likely to respond to immunotherapy. The goal is to see if the treatment is safe and can shrink tumors before surgery. Participants will receive the drugs for about 12 weeks, then have surgery to remove the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Nanjing Medical Unviersity
Nanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.